
FDA Issues Final Elemental Impurities Guidance
FDA publishes the final Q3D Elemental Impurities guidance.
FDA published the final
The guidance applies to new finished drug products and new drug products that contain existing drug products (i.e., products containing purified proteins and polypeptides, their derivatives, and products of which they are components, and drug products containing synthetically produced polypeptides, polynucleotides, and oligosaccharides). Not covered in the guidance are herbal products, radiopharmaceuticals, vaccines, cell metabolites, DNA products, allergenic extracts, cells, whole blood, cellular blood components or blood derivatives, dialysate solutions not intended for systemic circulation, elements that are intentionally included in the drug product for therapeutic benefit, gene therapy products, cell therapy products, or tissue engineering products.
The guidance will go into effect for existing products 36 months after publication.
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.